During this webcast, there will be a comprehensive discussion on five separate topics involving TAVR and the benefits to patients. Data from the PARTNER II trial, the SAPIEN 3 trial, and the BRAVO 3 trial, which questions the use of bivalirudin as an alternative to heparin, will be discussed. The other two informative discussions will cover the use of 4-D CT and the cardiac function of patients undergoing valve replacements and the use of warfarin to decrease thrombosis. The webcast will address upcoming trials and data that will help the viewer identify changes to and improvements of TAVR in the future. read more...
Click Here to access this CME Program
March 4th, 2016
September 4th, 2016